From this observational study, we have been able to obtain and test these findings about the risk of G-CSF treatment in patients with neutropenic cancer and infected by SARS-CoV-2 by applying appropriate adjustment variables, but further studies are required to confirm these findings and to obtain more information about aspects such as the involvement of cancer therapies, type of tumor, vaccination status, etc. This evidence concerns the gene CSF3 and cancer.